528 results about "Thymus Glands" patented technology

The invention belongs to the technical field of medical image assistance, and particularly relates to an auxiliary stereo imaging system and method for a complex chest trauma operation. By integrating multi-modal image data, real-time three-dimensional space capture, dynamic correction and risk score driven view adjustment, accurate assistance of the thymotomy operation process is achieved, the accuracy and safety of the operation are improved, the operation risk and operation difficulty are remarkably reduced, and the operation efficiency is improved. By acquiring and processing multi-modal image data in real time, a high-precision three-dimensional anatomical structure model containing thymus tissues, a blood vessel network and nerve distribution can be constructed, a visual surgical navigation view is provided for a doctor, meanwhile, a dynamic correction technology is adopted, thymus displacement parameters caused by thoracic cavity respiratory movement of a patient are monitored in real time, and the thoracic cavity of the patient can be accurately and accurately positioned. And on the basis, the real-time three-dimensional space data is dynamically adjusted, so that the spatial synchronization of the image data and the anatomical structure is ensured, and the navigation error caused by respiratory movement is effectively avoided.

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.

The invention discloses preparation of a whey protein peptide mixture with immune and muscle-building effects, and relates to the technical field of food processing and bioengineering. The neutral protease is adopted and the pH is adjusted, so that the enzymolysis efficiency is effectively improved, and the enzymolysis time is greatly shortened; meanwhile, the whey protein peptide which is uniform in molecular weight distribution, free of peculiar smell and good in thermal stability is successfully prepared by accurately controlling enzymolysis conditions and combining microbial fermentation. The protein peptide can effectively improve thymus indexes and spleen indexes, enhance the proliferation capacity of splenic lymphocytes and the activity of NK cells, play an excellent immune regulation role and have a remarkable muscle building effect. The preparation process has the advantages of high efficiency, low cost, simplicity, convenience and the like, gives consideration to high quality and high functionality of the product, and has great application value.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate-to-severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, comprising selecting a subject having AD and an elevated level of at least one biomarker selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin-5 (IL-5), eosinophil count, and lactate dehydrogenase (LDH) relative to a control.

The invention belongs to the technical field of medicines, and relates to a homogeneous polysaccharide with immunoregulatory activity and a preparation method and application thereof. The homogeneous polysaccharide FPS1-2 with immunoregulation activity is extracted and can recover the body weight of immunocompromised mice, increase spleen indexes and thymus indexes, improve spleen lesion conditions, promote proliferation of CD4 + T cells and release of related cell factors, recover metabolites such as short-chain fatty acids in intestinal tracts and improve the immune regulation activity of the mice. The flora type in the intestinal microbiota is improved. Therefore, the homogeneous polysaccharide has a good application prospect in preparation of functional food for enhancing immunity or medicines for treating immunosuppression.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method, application and product of a traditional Chinese medicine composition. The preparation method is characterized by comprising the following steps: firstly, adding water and auxiliaries into the ferula asafetida, the myrobalan, the rheum officinale and the turmeric, soaking, extracting, filtering, and merging filtrate to obtain an extracting solution and medicine residues; the auxiliary agent comprises sophorose ester and hydrogenated lecithin in a mass ratio of (2-4): 1; mixing the medicine residues with aspongopus, clove and radix aucklandiae, adding water and enzyme for enzymolysis, inactivating the enzyme, and filtering to obtain enzymatic hydrolysate; and finally, crushing the cordyceps sinensis, adding the extracting solution and the enzymatic hydrolysate, mixing, concentrating and drying to obtain the cordyceps sinensis extract. Water extraction medicine residues, aspongopus, clove and radix aucklandiae are extracted by adopting a special process and a specific enzyme, and the extract is compatible with other components, so that the immunity of the organism can be better improved, and the thymus coefficient and the spleen index are improved.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate-to-severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, comprising selecting a subject having AD and an elevated level of at least one biomarker selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin-5 (IL-5), eosinophil count, and lactate dehydrogenase (LDH) relative to a control.

The invention relates to a detection kit and a detection method for EBV latent infection of epithelial cells and B cells in a thymus and salivary gland tissue microenvironment, and the detection method comprises the following steps: dyeing thymus and salivary gland tissues by coupling quantum dots and a specific antibody; the conjugate of the quantum dots and the specific antibody is combined with a specific antigen of a tissue sample to realize marking of EBV latent infection epithelial cells and B cells by the quantum dots. According to the invention, the existing multicolor immunofluorescence technology is improved, the specific antibody and the quantum dot are coupled and purified and then are directly combined with the antigen on the tissue slice to realize direct marking of the quantum dot coupled antibody on the tissue sample, so that EBV latent infection cells in the thymus and salivary gland tissue microenvironment are positioned and quantified; the virus infection condition of the patient is evaluated from the pathogenesis level, the disadvantage that the previous evaluation means are limited is overcome, and the method has good sensitivity and accuracy.

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

The invention discloses a construction method and application of thymus organoid, and the method comprises the following steps: differentiating pluripotent stem cells into thymus organoid under a suspension culture condition through combined and matched use of small molecule compounds and small molecule proteins, according to the method disclosed by the invention, the thymus organoid of which the structure and the function are closer to those of natural thymus can be efficiently obtained.

The invention discloses a cord blood-derived hematopoietic stem cell as well as an amplification method and application thereof. The method comprises the step of culturing umbilical cord blood mononuclear cells by using a culture medium containing thymus active polypeptide, stem cell growth factors and heat shock protein. According to the method for amplifying the umbilical cord blood-derived hematopoietic stem cells, the proliferation efficiency of umbilical cord blood mononuclear cells can be remarkably improved, and the amplification capacity of umbilical cord blood immune cells (NK cells) is improved by more than 5 times compared with that of a traditional method.

Described herein is a topical formulation. The topical formulation includes a thymine-thymine compound including Formula (1) and a solvent system. The topical formulation includes about 0.01 wt% to about 10 wt% of the thymine-thymine compound, based on total weight of the formulation. A method of preparing the topical formulation is also provided.

Described herein are antibodies, or antigen binding fragments thereof, that bind thymic stromal lymphopoietin (TSLP) and OX40L in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and TSLP biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-TSLP and anti-OX40L antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP and / or OX40L.

The invention discloses a medicine for treating tumors containing TP53 gene mutation. The medicine comprises a thymine DNA (Deoxyribose Nucleic Acid) glycosylase (TDG for short) inhibitor and pharmaceutically acceptable auxiliary components of the thymine DNA glycosylase (TDG for short) inhibitor. The TDG inhibitor used in the invention can effectively inhibit human TDG protein expression, and has a good treatment effect on TP53 gene mutation-containing tumors.

The invention relates to the technical field of microorganisms, and particularly discloses application of bifidobacterium animalis subsp. Lactis BAPerfectuus006 in improving qi deficiency and enhancing immunity. The bifidobacterium animalis subsp. Lactis BAPerfectuus006 provided by the invention is separated from intestinal tracts of healthy infants, has no drug resistance, no hemolytic activity, no pathogenicity, no virulence genes and transferable drug-resistant genes, and can be used for preparing the health-care food. The Jiangjing pill is a safe strain, can significantly improve the qi deficiency symptom, delay weight loss and reduce lactic acid accumulation, has better improvement effects in the aspects of qi deficiency symptom, thymus index, spleen index, holding power, suspension capacity and the like than Guangjing pill for tonifying middle-Jiao and Qi under the same condition, and also has the effect of enhancing immunity.

Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.

The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

The invention provides a thymus organ culture kit and application thereof. Specifically, the invention provides a culture reagent / kit for organoid culture, and the culture reagent / kit comprises a culture medium selected from the following groups: (A) an R-B27 culture medium which is an RPMI 1640 culture medium supplemented with B-27, ascorbic acid and Primocin; and / or (B) an organ-like (ATO) complete culture medium, wherein the ATO complete culture medium is an RPMI 1640 culture medium in which B-27, ascorbic acid, Primocin, RhIL-7 and RhFLT3L are supplemented. The organoid culture reagent / kit provided by the invention has the advantages of high success rate of organoid culture, short time required by primary cell passage and capability of reducing the time for constructing thymus organoids.

The invention discloses a synthesis method of 2 '-fluoro-2'-deoxyguanosine. According to the method, thymine nucleoside phosphorylase and purine nucleoside phosphorylase are used as biocatalysts, and 2 '-fluoro-2'-deoxyuridine and guanine are used as substrates to synthesize the 2 '-fluoro-2'-deoxyguanosine. Compared with a chemical method, the production cost is greatly reduced; meanwhile, the synthesis method can effectively solve the problem that the product is difficult to separate.

The invention belongs to the technical field of medicines, and particularly relates to application of hordenine in preparation of a medicine for treating and relieving tissue damage. It is found that hordenine shows the effect of relieving immunological liver injury and spleen injury on an animal model, therefore, the application of hordenine to preparation of the medicine for treating and relieving tissue injury is provided, hordenine shows a remarkable curative effect, symptoms of immunological liver injury and pathological injury of spleen and thymus can be effectively relieved, and the hordenine can be used for preparing the medicine for treating and relieving tissue injury. The conditions include abnormal liver cell morphology, inflammatory cell tissue infiltration, pathological injuries such as extravasated blood and necrosis, cell apoptosis and the like. Animal experiments show that no obvious toxic reaction or side effect is observed while the hordenine is used for relieving immunological liver injury, spleen injury and thymus injury.

The invention discloses plant lactobacillus and application thereof in immunoregulation and intestinal environment improvement, and relates to the technical field of microorganisms. The invention provides a strain of plant lactobacillus LIHUO 05, and the preservation number of the plant lactobacillus LIHUO 05 is CGMCC (China General Microbiological Culture Collection Center) No.36240. The invention also provides a preparation method of the plant lactobacillus LIHUO 05. The plant lactobacillus LISUO 05 can be used for promoting macrophages to secrete TNF (Tumor Necrosis Factor)-alpha and IL-1beta; the thermally inactivated strain LIHUO 05 has a certain immunoregulation effect on the body weight, thymus index and TNF-alpha content in serum of immunocompromised mice. Meanwhile, the phytobacterium plantarum LIHUO 05 can change the colon flora structure in the intestinal tract, improve the relative abundance of beneficial bacteria and adjust the variety and number of colon metabolites in the intestinal tract, and has a certain effect of improving the intestinal tract environment.

The invention belongs to the technical field of poultry feed additives, provides a feed additive for improving growth and skeleton health of broiler chickens in a chronic stress state and application of the feed additive, and particularly relates to new application of the feed additive in broiler chicken feed additives with high-density stress and heat stress. And the used lipoic acid and chromium methionine are safe, free of drug resistance, free of adverse reaction and low in price. The feed additive comprises lipoic acid and chromium methionine, and the addition amount of the lipoic acid is 300mg / kg; and chromium methionine is 400 [mu] g / kg. The additive can influence the bone quality and improve the bone breaking strength, the bone-body ratio and the weight of the heat stress broiler chicken. The additive can improve the immune organ index of the broiler chicken and improve the relative weight of spleen, thymus and abdominal fat. The feed additive can improve the oxidation resistance and immune performance of the broiler chickens under high-density stress and heat stress, relieve bone injury, and possibly protect bone health of the broiler chickens by removing free radicals in the body and maintaining calcium and phosphorus metabolic balance in the body.

The invention discloses application of neutrophile granulocyte number level in prediction of tumor treatment effect. Through verification of the embodiment of the invention, the number level of neutrophils in blood of a tumor patient before treatment is closely associated with the curative effect of tumor treatment, especially OH2 treatment, and the applicable tumor adaptation diseases are common; comprising at least one of melanoma, esophageal cancer, right breast invasive ductal cancer, intestinal cancer, head and neck tumor, gastric cancer, ovarian cancer, biliary system tumor, left foot back squamous cell carcinoma, sarcoma and osteosarcoma, lung cancer, thymosquamous cell carcinoma and brain glioma. In the application disclosed by the invention, the threshold value of the number of neutrophils for predicting the tumor treatment effect is 3.5 * 10 < 9 > / L; the treatment is predicted to be effective when the number of sexual granulocytes in a tumor patient is below 3.5 * 109 / L before the tumor patient is treated, and the treatment is predicted to be ineffective or invalid when the number of sexual granulocytes in the tumor patient is higher than 3.5 * 109 / L. The application method is simple, low in cost and good in stability, and can become a potential prediction means for clinicians.

The invention provides application of combined use of thymopentin, salinomycin and IR780 iodide in preparation of a medicine for treating and inhibiting tumor dryness. The invention also provides a pharmaceutical composition for inhibiting tumor dryness. The invention relates to an endoplasmic reticulum stress nano inducer (DTSS) based on salinomycin, which is used for synergistically inhibiting the dryness of cancer cells and effectively sensitizing cancer immunotherapy. The endoplasmic reticulum targeted phototherapy drug s-780 is prepared by coupling p-toluene sulfonamide and IR780 iodide (IR780), is assembled together with thymopentin and salinomycin, and is finally functionalized by biotin to obtain a delivery nano-platform (DTSS) at a specific site, so that systemic anti-tumor immune response can be effectively activated, metastasis and recurrence of cancers can be inhibited, and the application prospect is wide. And a promising solution is provided for sensitizing cancer immunotherapy by inhibiting cancer cell dryness.

A phosphorothioate-containing RNA molecule that includes the nucleotide sequence: 5'-NCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGC-3' (SEQ ID NO: 1), where N is uracil or thymine, is provided. The RNA molecule can include one or more phosphorothioate bonds between nucleic acid residues in one or more pairs (e.g., between nucleic acid residues in each pair) of consecutive nucleic acid residues within SEQ ID NO: 1. The RNA molecule and compositions thereof find use in treating muscle disorders, such as muscular dystrophy, heart conditions, such as heart failure or myocardial infarction, and / or conditions associated with inflammation and / or fibrosis.